Polmacoxib
Polmacoxib was approved by the Korean Ministry of Food and Drug Safety (MFDS) on Feb 05, 2015. It was originally developed by CrystalGenomics, then it signed an agreement for the commercialization of polmacoxib in South Korea with Dong-A in August. It is marketed as Acelex® in KR.
Polmacoxib is a cyclooxygenase 2 (COX-2) inhibitor, for the treatment of osteoarthritis.
Acelex® is available as capsules for oral use, containing 2 mg of polmacoxib. The recommended dose is 2 mg once daily.
General Information
Update Date：2016-03-22
- Drug Name：
- Polmacoxib
- Research Code：
- CG-100649
- Trade Name：
- Acelex®
- MOA：
- COX-2 inhibitor
- Indication：
- Osteoarthritis (OA)
- Status：
- Approved
- Company：
- CrystalGenomics (Originator) , Dong-A
- Sales：
- ATC Code：
Approved Countries or Area
Update Date：2016-03-22
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2015-02-05 | First approval | Acelex | Osteoarthritis (OA) | Capsule | 2 mg | CrystalGenomics |
Chemical Structure
Update Date：2016-03-22
|
Molecular Weight | 361.39 | ||||||||||||
| Formula | C18H16FNO4S | |||||||||||||
| CAS No. | 301692-76-2 (Polmacoxib); | |||||||||||||
| Chemical Name | Benzenesulfonamide, 4-[3-(3-fluorophenyl)-4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl]- | |||||||||||||
| Polmacoxib （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Related Patents
Update Date：2016-03-29
Synthesis & Impurities
Update Date：2016-05-12
